Highlights:
• Two lead R&D programs progressing as planned and on-budget
• Brain injury program leads to discovery of a new generation of more potent drug candidates
• PCSK9 (cholesterol-lowering) program remains on-track towards goal of an oral, once a day tablet
• Steps being taken to minimise any potential disruption to business operations by COVID-19
For more information, please download the attached PDF
Download this document
